Content area
Abstract
Dr. Wiedermann commented on our systematic review and meta-regression for the sources of heterogeneity in trials reporting HES 130/0.4 or 0.42 associated excess mortality in septic patients [1] that the pooled analysis of mortality, which showed neither benefit nor harm, might be influenced by trials of low-quality. More importantly, the uncertainty of chosen the threshold for the significant level for interaction test is still controversial. [...]the significant results of subgroup should be interpreted with cautions. [...]information from bedside (such as incomparable subsequent effects in fluid therapy) should be considered with priority over statistics in interpreting the results of available RCTs in evaluating the impact of any clinical intervention on mortality in critically ill patients. 1. Sources of heterogeneity in trials reporting hydroxyethyl starch 130/0.4 or 0.42 associated excess mortality in septic patients: A systematic review and meta-regression. Medical Research and Biometrics Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital,...